• 1
    Ratner R, Eden J, Wolman D, Greenfield S, Sox H, eds. Initial national priorities for comparative effectiveness research. In: Medicine Io, ed. Washington DC: National Academies Press; 2009.
  • 2
    Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Ann Intern Med. 2009; 151: 203205.
  • 3
    Siegel CA. Accidentally ASCENDing into comparative effective research for inflammatory bowel disease. Gastroenterology. 2009; 137: 18801882.
  • 4
    Ericsson KaSH. Protocol Analysis: Verbal Reports as Data (Revised Edition). Cambridge, MA: MIT Press, 1993.
  • 5
    DeWalt DA, Rothrock N, Yount S, et al. Evaluation of item candidates: the PROMIS qualitative item review. Med Care. 2007; 45: S1221.
  • 6
    Brook R. The RAND/UCLA Appropriateness Method. Clinical Practice Guideline Development: Methodology Perspectives. Rockville, MD: AHCR; 1994.
  • 7
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 13831395.
  • 8
    D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660887.
  • 9
    Slattery E, Harewood GC. Comparative effectiveness research in inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17: E4647.